Because the IHC-based CD133 classification is commonly used, further investigation is needed to ascertain whether the transcriptome profiles of CD133+ and CD133- primary GCs are too heterogeneous to obtain robust signatures as well as to determine the extent to which the tumor purity or the stromal component impact the clinical evaluation of expression-based CD133 signatures. This evidence concerns the gene PROM1 and neoplasm.